Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 14 May 2026 for Apellis Pharmaceuticals, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Kelley Boucher: trading record in brief
Kelley Boucher (senior executive) discloses dealings in Apellis Pharmaceuticals, Inc. to SEC (Form 4). We count 5 filings; the first trade dates from 28 May 2025 and the latest from 14 May 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Most recently, on 14 May 2026, the filings show a transaction in Apellis Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Kelley Boucher
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
127,804 sharesCommon StockSEC:0001193125-26-224589:0
30,146 shares0Common StockSEC:0001492422-26-000079:0
30,476 shares0Common StockSEC:0001127602-25-021104:0
45,095 shares0Common StockSEC:0001127602-25-017286:0
22,087 shares0Common StockSEC:0001127602-25-015877:0
5 of 5 declarations
